Raleigh Capital Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Raleigh Capital Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-876	Closed	-$20.1K	–	1067
2023 Q4	$20.1K	Buy	876 +225	+35%	+$4.52K	0.01%	439
2023 Q3	$13.3K	Sell	651 -166	-20%	-$3.73K	0.01%	456
2023 Q2	$19.1K	Buy	817 +2	+0.2%	+$48	0.01%	395
2023 Q1	$19K	Buy	+815	New	+$20.4K	0.01%	380

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Raleigh Capital Management's IDNA Position: Q1 2024 in Review

Raleigh Capital Management sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2024, closing a stake of 876 shares — an estimated $20.1K sold.

Raleigh Capital Management first reported a position in IDNA in Q1 2023 and held it in 4 quarters. The position peaked at $20.1K in Q4 2023. 63 funds tracked by Wall St. Rank hold IDNA as of Q1 2024.

Raleigh Capital Management reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2024 after selling out during the quarter.
Raleigh Capital Management sold 876 iShares Genomics Immunology and Healthcare ETF shares in Q1 2024, an estimated $20.1K.
Raleigh Capital Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2023 and held it in 4 quarters.
Raleigh Capital Management's iShares Genomics Immunology and Healthcare ETF position peaked at $20.1K in Q4 2023.
63 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.